BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 97
- Registration Number
- NCT01523171
- Locations
- 🇺🇸
Investigational Site Number 840003, San Francisco, California, United States
🇺🇸Investigational Site Number 840005, Atlanta, Georgia, United States
🇺🇸Investigational Site Number 840004, San Francisco, California, United States
Japanese Phase 1 Multiple Ascending Dose Study
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo matching with BMS-823778
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT01515202
- Locations
- 🇯🇵
Local Institution, Hachioji-Shi, Tokyo, Japan
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
- Conditions
- Melanoma
- Interventions
- Biological: Ipilimumab
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 831
- Registration Number
- NCT01515189
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸The Angeles Clinic And Research Institute, Los Angeles, California, United States
🇺🇸University Of California Los Angeles, Los Angeles, California, United States
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 19
- Registration Number
- NCT01514864
- Locations
- 🇺🇸
H. Lee Moffitt Cancer & Research Institute, Tampa, Florida, United States
🇨🇦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
🇬🇧Local Institution, Gwent, United Kingdom
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
- Conditions
- Advanced Cutaneous Melanoma
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1411
- Registration Number
- NCT01511913
- Locations
- 🇺🇸
Mid Ohio Onc/Hem, Inc, Columbus, Ohio, United States
🇬🇷Local Institutio, Alexandroupolis, Greece
🇬🇷Local institution, Goudi, Athens, Greece
A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients
- Conditions
- Hepatitis C
- Interventions
- Drug: BMS-650032 (Asunaprevir)
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 224
- Registration Number
- NCT01497834
- Locations
- 🇯🇵
Local Institution, Chuo-shi, Yamanashi, Japan
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 605
- Registration Number
- NCT01492426
- Locations
- 🇺🇸
The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸Atlanta Medical Center, Atlanta, Georgia, United States
🇺🇸Medical Associates Research Group, San Diego, California, United States
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: Placebo matching BMS-241027
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT01492374
- Locations
- 🇺🇸
Associated Neurologists Of Southern Connecticut, P.C., Fairfield, Connecticut, United States
🇺🇸Palm Beach Neurological Center Advanced Research Consultants, Palm Beach Gardens, Florida, United States
🇺🇸Compass Research, Llc, Orlando, Florida, United States
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1850
- Registration Number
- NCT01492504
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Nashville Medical Research Institute, Nashville, Tennessee, United States
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Placebo matching with BMS-986001
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 297
- Registration Number
- NCT01489046
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Jacobi Medical Center, Bronx, New York, United States
🇹🇭Local Institution, Nontaburi, Thailand